Uncategorized

On a recent business trip to China, I was automatically assumed to be an interpreter or assistant because I was helping with communication on both sides. I had to assert myself and remind my colleagues that I, too, had original thoughts to contribute. This small example shines light on the issue of how Asian women are often perceived. We are seen as competent and hard-working, partly due to stereotypes, but not necessarily powerful or influential. In fact, projecting an image of power can invoke some resentment and cause discomfort. A man I once supervised admitted to me that he was not used to having a woman as manager. At least he was honest, which made it easier to work out the problem.

ROCKVILLE, MARYLAND, February 11, 2013 – BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the appointment of GenVec, Inc. President and Chief Executive Officer Cynthia L. Collins to its Board of Directors. BHI also announced that BHI Founding Board Member Jerry Parrott, formerly with Human Genome Sciences, has stepped down from his board seat but will continue to remain active on BHI’s Commercial Relevance Advisory Board.

ROCKVILLE, MARYLAND, February 27, 2013 – BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the formation of its Commercial Relevance Advisory Board (CRAB). Members of the CRAB represent diverse business and academic organizations from throughout the region, such as venture capital firm New Enterprise Associates, Ernst & Young, the Howard Hughes Medical Institute, the University of Maryland (UMD), Johns Hopkins University, and leading biotechnology companies.

BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the formation of its Commercial Relevance Advisory Board (CRAB). Members of the CRAB represent diverse business and academic organizations from throughout the region, such as venture capital firm New Enterprise Associates, Ernst & Young, the Howard Hughes Medical Institute, the University of Maryland (UMD), Johns Hopkins University, and leading biotechnology companies.

The CRAB will assist BHI in evaluating market-relevant research and product development opportunities as well as help determine the commercial applicability of emerging entrepreneurs, companies and their science or technology. BHI will utilize feedback from CRAB members as part of its due diligence process for establishing formal client relationships and potentially future investments.

The young Leiden-based biotech company Mimetas has closed an agreement with a regional development company from the state of Maryland, USA. Biohealth Innovation Inc., in which regional governments, universities and companies collaborate, will assist in setting up a US branch to find customers and business partners for Mimetas in the USA.

BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the appointment of GenVec, Inc. President and Chief Executive Officer Cynthia L. Collins to its Board of Directors. BHI also announced that BHI Founding Board Member Jerry Parrott, formerly with Human Genome Sciences, has stepped down from his board seat but will continue to remain active on BHI’s Commercial Relevance Advisory Board.

“Cindy’s addition to the BHI Board of Directors provides us with access to and perspective from another talented biopharma leader from this region,” said Scott Carmer, BioHealth Innovation, Inc. Chairman of the Board and Executive Vice President of Commercial Operations at MedImmune. “Her tremendous depth and breadth of experience across the industry, particularly with regard to diagnostics as well as therapeutic areas ranging from antivirals to oncology, will be an asset to the companies we work with who are seeking to commercialize biohealth innovations.